In Vivo Characterization of (−)(−)MCL-144 and (+)(−)MCL-193: Isomeric, Bivalent Ligands with Mu/Kappa Agonist Properties

@article{Mathews2008InVC,
  title={In Vivo Characterization of (−)(−)MCL-144 and (+)(−)MCL-193: Isomeric, Bivalent Ligands with Mu/Kappa Agonist Properties},
  author={Jennifer L. Mathews and Brian Shane Fulton and S Stevens Negus and John L Neumeyer and Jean M. Bidlack},
  journal={Neurochemical Research},
  year={2008},
  volume={33},
  pages={2142-2150}
}
Once opioid receptor dimers were postulated, a goal has been to synthesize and screen novel opioids, with the hope of furthering our knowledge of the structure-activity relationship of opioid ligands with the opioid receptors. The aim of the current study was to address whether two isomeric bivalent ligands would have pharmacological differences after central administration, in vivo. The two compounds, (−) bis(N-cyclobutylmethyl-morphinan-3-yl) sebacoylate dihydrochloride (MCL-144) and 1−((+)N… 
Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile.
TLDR
Production and evaluation of bivalent ligands is an emerging field in drug design and for anaesthesia, analgesics that are designed not to be highly selective morphine-like (MOP) ligands represents a new avenue for the production of useful drugs for chronic pain.
Novel pharmaco-types and trafficking-types induced by opioid receptor heteromerization
TLDR
This review attempts to highlight some of the latest developments with regard to opioid receptor heteromer trafficking and pharmacology.
Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.
TLDR
Bivalent morphinan compounds containing ester linkers were synthesized and their binding affinities at the mu, delta, and kappa opioid receptors determined, and 4a and 4b were partial agonists at the kappa and micro receptors in the [(35)S]GTPgammaS binding assay.
Rational Modification of the Biological Profile of GPCR Ligands through Combination with Other Biologically Active Moieties
TLDR
Some representative examples for these approaches at different GPCRs are presented, showing the versatility of this approach, with a focus on the own work and references to related articles and reviews.
Design Strategies for Bivalent Ligands Targeting GPCRs
TLDR
The molecular descriptors of the bivalent ligands that exhibit in vivo activity are distils, as well as their ability to access the central nervous system is highlighted.
...
...

References

SHOWING 1-10 OF 28 REFERENCES
Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
TLDR
The present study characterizes the pharmacological profile of a bivalent morphinan that was shown to be a kappa opioid receptor agonist and a mu opioid receptors agonist/antagonist.
Design, synthesis, and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as selective muscarinic agonists.
TLDR
Bivalent compounds containing essentially two agonist pharmacophores within the same molecule were synthesized and tested for receptor binding affinity and muscarinic agonist activity, resulting in improved water solubility, binding affinity, and agonist potency.
Design and Synthesis of Novel Dimeric Morphinan Ligands for κ and μ Opioid Receptors
TLDR
A novel series of morphinans were synthesized, and their binding affinity at and functional selectivity for micro, delta, and kappa opioid receptors were evaluated, and it was observed that the affinity of these ligands was sensitive to the character and length of the spacer.
Serotonin dimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT(1B/1D) agonists.
TLDR
Results analysis supports the hypothesis that the important increase in potency of the serotonin dimers can be attributed to the presence of two serotonin pharmacophores in the same molecule, while the enhanced selectivity for 5-HT(1B/1D) receptor subtypes may be due to the position of the spacer attachment to serotonin.
Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at μ, δ, and κ opioid receptors
TLDR
The data suggest that the stereochemistry of the pharmacophores, the N-substituents of the Pharmacophore, ester linkages, and the spacer length were crucial factors for optimum interactions of such ligands at opioid receptor binding sites.
Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
TLDR
The data suggest that the stereochemistry of the pharmacophores, the N-substituents of the Pharmacophore, ester linkages, and the spacer length were crucial factors for optimum interactions of such ligands at opioid receptor binding sites.
Interaction of Bivalent Ligand KDN21 with Heterodimeric δ-κ Opioid Receptors in Human Embryonic Kidney 293 Cells
TLDR
Interactions of members of the KDN series with δ-κ heterodimers through competition binding using selective ligands and the mitogen-activated protein kinase (MAPK) assay support the idea that the organization of δ and κ receptors as heterodIMers gives rise to δ1 and δ2 phenotypes.
A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes.
TLDR
A conceptual model is presented to explain the organizational differences between the opioid receptors that give rise to the phenotypes (delta- and kappa-opioid receptor phenotypes) and it is suggested that KDAN-18 (2) bridges phenotypic delta(2)- and k Kappa(1)-receptors.
Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test.
The duration of antagonistic action of nor-binaltorphimine (nor-BNI), a kappa antagonist, of antinociception resulting from selective opioid agonists, was examined using the mouse tail-flick assay as
SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist.
The present study has investigated the pharmacology of SNC 80, a nonpeptidic ligand proposed to be a selective delta agonist in vitro and in vivo. SNC 80 was potent in producing inhibition of
...
...